Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Ovarian Neoplasms | 199 | 2024 | 4919 | 16.410 |
Why?
|
Phthalazines | 33 | 2024 | 397 | 7.410 |
Why?
|
Neoplasm Recurrence, Local | 78 | 2024 | 9442 | 5.000 |
Why?
|
Piperazines | 28 | 2024 | 2553 | 3.930 |
Why?
|
Cystadenocarcinoma, Serous | 23 | 2021 | 480 | 3.590 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 74 | 2024 | 11886 | 3.460 |
Why?
|
Endometrial Neoplasms | 25 | 2023 | 1386 | 3.440 |
Why?
|
Maytansine | 10 | 2024 | 88 | 3.410 |
Why?
|
Indazoles | 15 | 2023 | 306 | 3.340 |
Why?
|
Immunoconjugates | 15 | 2024 | 976 | 3.320 |
Why?
|
Peritoneal Neoplasms | 28 | 2024 | 714 | 2.990 |
Why?
|
Neoplasms, Glandular and Epithelial | 18 | 2018 | 489 | 2.980 |
Why?
|
Fallopian Tube Neoplasms | 19 | 2024 | 329 | 2.960 |
Why?
|
Folate Receptor 1 | 11 | 2024 | 41 | 2.830 |
Why?
|
Genital Neoplasms, Female | 16 | 2024 | 538 | 2.650 |
Why?
|
Antineoplastic Agents | 59 | 2024 | 13698 | 2.520 |
Why?
|
BRCA2 Protein | 25 | 2024 | 803 | 2.290 |
Why?
|
BRCA1 Protein | 27 | 2024 | 1156 | 2.200 |
Why?
|
Piperidines | 14 | 2022 | 1667 | 2.030 |
Why?
|
Drug Resistance, Neoplasm | 40 | 2024 | 5342 | 2.020 |
Why?
|
Quinazolines | 10 | 2024 | 1373 | 1.580 |
Why?
|
Paclitaxel | 28 | 2023 | 1735 | 1.420 |
Why?
|
Carboplatin | 23 | 2024 | 799 | 1.210 |
Why?
|
Disease-Free Survival | 40 | 2023 | 6856 | 1.210 |
Why?
|
Female | 268 | 2024 | 397515 | 1.150 |
Why?
|
Neoplasms, Cystic, Mucinous, and Serous | 5 | 2020 | 196 | 1.140 |
Why?
|
Angiogenesis Inhibitors | 10 | 2018 | 2059 | 1.120 |
Why?
|
Platinum | 9 | 2023 | 222 | 1.050 |
Why?
|
Mixed Tumor, Mullerian | 7 | 2009 | 55 | 1.050 |
Why?
|
Isoxazoles | 3 | 2024 | 233 | 1.000 |
Why?
|
Deoxycytidine | 11 | 2024 | 888 | 0.930 |
Why?
|
Drug Administration Schedule | 27 | 2020 | 4862 | 0.890 |
Why?
|
Pyrazines | 5 | 2024 | 1206 | 0.880 |
Why?
|
CA-125 Antigen | 12 | 2024 | 281 | 0.840 |
Why?
|
Humans | 287 | 2024 | 768970 | 0.830 |
Why?
|
Germ-Line Mutation | 15 | 2020 | 1887 | 0.830 |
Why?
|
Genes, BRCA1 | 12 | 2021 | 756 | 0.830 |
Why?
|
Poly(ADP-ribose) Polymerases | 4 | 2018 | 428 | 0.790 |
Why?
|
DNA Repair | 6 | 2019 | 2054 | 0.790 |
Why?
|
Aged | 134 | 2024 | 171786 | 0.770 |
Why?
|
Carcinoma, Endometrioid | 4 | 2023 | 277 | 0.770 |
Why?
|
Quality of Life | 18 | 2024 | 13510 | 0.750 |
Why?
|
DNA Mismatch Repair | 3 | 2023 | 432 | 0.730 |
Why?
|
DNA Polymerase II | 3 | 2019 | 104 | 0.730 |
Why?
|
Middle Aged | 144 | 2024 | 223737 | 0.720 |
Why?
|
Genes, BRCA2 | 9 | 2021 | 593 | 0.700 |
Why?
|
Desensitization, Immunologic | 8 | 2024 | 558 | 0.670 |
Why?
|
Adenocarcinoma, Clear Cell | 2 | 2019 | 218 | 0.670 |
Why?
|
Chemotherapy, Adjuvant | 13 | 2022 | 3554 | 0.660 |
Why?
|
Aged, 80 and over | 58 | 2024 | 59739 | 0.660 |
Why?
|
Platinum Compounds | 5 | 2019 | 95 | 0.640 |
Why?
|
Genomic Instability | 4 | 2024 | 715 | 0.620 |
Why?
|
Azepines | 3 | 2019 | 329 | 0.610 |
Why?
|
Organoplatinum Compounds | 12 | 2020 | 408 | 0.590 |
Why?
|
Doxorubicin | 15 | 2024 | 2234 | 0.590 |
Why?
|
Drug Hypersensitivity | 8 | 2024 | 923 | 0.580 |
Why?
|
Antibodies, Monoclonal | 13 | 2023 | 9264 | 0.570 |
Why?
|
Adult | 122 | 2024 | 223851 | 0.570 |
Why?
|
Cisplatin | 9 | 2021 | 1661 | 0.560 |
Why?
|
Carcinoma, Papillary | 3 | 2013 | 793 | 0.560 |
Why?
|
Protein Kinase Inhibitors | 13 | 2024 | 5707 | 0.560 |
Why?
|
Pyrimidines | 6 | 2019 | 3048 | 0.550 |
Why?
|
Uterine Neoplasms | 6 | 2021 | 1424 | 0.550 |
Why?
|
Immunotherapy | 5 | 2022 | 4756 | 0.540 |
Why?
|
Neoplasm Staging | 31 | 2021 | 11262 | 0.510 |
Why?
|
Peripheral Nervous System Diseases | 1 | 2021 | 716 | 0.510 |
Why?
|
Anilides | 1 | 2018 | 414 | 0.510 |
Why?
|
Receptor, erbB-2 | 9 | 2022 | 2606 | 0.490 |
Why?
|
bcl-X Protein | 3 | 2024 | 412 | 0.490 |
Why?
|
Mutation | 28 | 2024 | 30266 | 0.490 |
Why?
|
Morpholines | 2 | 2019 | 584 | 0.480 |
Why?
|
Pyrimidinones | 3 | 2024 | 386 | 0.480 |
Why?
|
Breast Neoplasms | 17 | 2022 | 21188 | 0.470 |
Why?
|
Kaplan-Meier Estimate | 13 | 2019 | 6547 | 0.470 |
Why?
|
Topotecan | 8 | 2023 | 131 | 0.470 |
Why?
|
Maximum Tolerated Dose | 7 | 2019 | 899 | 0.470 |
Why?
|
Survival Rate | 16 | 2020 | 12873 | 0.470 |
Why?
|
Pyrazoles | 5 | 2021 | 2029 | 0.460 |
Why?
|
Aminopyridines | 2 | 2019 | 580 | 0.450 |
Why?
|
Salvage Therapy | 2 | 2020 | 1277 | 0.450 |
Why?
|
Immune System | 1 | 2019 | 800 | 0.440 |
Why?
|
Receptors, Vascular Endothelial Growth Factor | 4 | 2016 | 664 | 0.440 |
Why?
|
Xenograft Model Antitumor Assays | 10 | 2024 | 3621 | 0.440 |
Why?
|
Uterine Cervical Neoplasms | 3 | 2019 | 2044 | 0.430 |
Why?
|
Carcinoma | 7 | 2023 | 2340 | 0.430 |
Why?
|
Gastrointestinal Diseases | 1 | 2021 | 1204 | 0.420 |
Why?
|
Neoplasms | 24 | 2024 | 22389 | 0.420 |
Why?
|
Combined Modality Therapy | 11 | 2022 | 8559 | 0.420 |
Why?
|
Genetic Testing | 4 | 2020 | 3591 | 0.410 |
Why?
|
Corneal Diseases | 1 | 2018 | 535 | 0.410 |
Why?
|
Quinoxalines | 1 | 2014 | 297 | 0.410 |
Why?
|
Thiazoles | 2 | 2022 | 1542 | 0.410 |
Why?
|
Survivors | 6 | 2013 | 2383 | 0.400 |
Why?
|
Sulfonamides | 4 | 2024 | 1981 | 0.390 |
Why?
|
Treatment Outcome | 45 | 2024 | 65480 | 0.390 |
Why?
|
Dose-Response Relationship, Drug | 14 | 2020 | 10765 | 0.370 |
Why?
|
Administration, Oral | 8 | 2020 | 4040 | 0.370 |
Why?
|
Receptors, Estrogen | 4 | 2022 | 2252 | 0.370 |
Why?
|
Loss of Heterozygosity | 2 | 2013 | 663 | 0.370 |
Why?
|
Colorectal Neoplasms, Hereditary Nonpolyposis | 1 | 2014 | 388 | 0.350 |
Why?
|
DNA Damage | 3 | 2019 | 2472 | 0.340 |
Why?
|
Taxoids | 7 | 2015 | 668 | 0.340 |
Why?
|
Antineoplastic Agents, Phytogenic | 6 | 2018 | 622 | 0.340 |
Why?
|
Clinical Trials, Phase III as Topic | 3 | 2022 | 878 | 0.340 |
Why?
|
Fatigue | 7 | 2023 | 1557 | 0.330 |
Why?
|
Randomized Controlled Trials as Topic | 10 | 2021 | 10400 | 0.320 |
Why?
|
Receptors, Progesterone | 3 | 2013 | 1159 | 0.320 |
Why?
|
Glucocorticoids | 1 | 2018 | 2167 | 0.320 |
Why?
|
Cyclodextrins | 2 | 2021 | 63 | 0.300 |
Why?
|
Enzyme Inhibitors | 6 | 2018 | 3726 | 0.300 |
Why?
|
Infusions, Intravenous | 8 | 2020 | 2231 | 0.300 |
Why?
|
Molecular Targeted Therapy | 7 | 2022 | 2830 | 0.300 |
Why?
|
Double-Blind Method | 10 | 2020 | 12467 | 0.290 |
Why?
|
Camptothecin | 3 | 2021 | 600 | 0.280 |
Why?
|
Pyridines | 2 | 2018 | 2895 | 0.280 |
Why?
|
Indoles | 4 | 2024 | 1836 | 0.280 |
Why?
|
Neoplastic Cells, Circulating | 1 | 2013 | 957 | 0.270 |
Why?
|
Prognosis | 22 | 2023 | 30046 | 0.270 |
Why?
|
Pyridones | 2 | 2024 | 819 | 0.270 |
Why?
|
Gene Expression Profiling | 7 | 2021 | 9549 | 0.260 |
Why?
|
Lymphocytes, Tumor-Infiltrating | 4 | 2020 | 1105 | 0.250 |
Why?
|
Gene Expression Regulation, Neoplastic | 13 | 2022 | 8664 | 0.250 |
Why?
|
Palliative Care | 6 | 2024 | 3644 | 0.250 |
Why?
|
Ligands | 2 | 2022 | 3283 | 0.250 |
Why?
|
Recurrence | 11 | 2023 | 8513 | 0.250 |
Why?
|
Sequence Analysis, DNA | 1 | 2016 | 4785 | 0.250 |
Why?
|
Mutation, Missense | 1 | 2014 | 2592 | 0.240 |
Why?
|
Intestinal Obstruction | 2 | 2005 | 433 | 0.240 |
Why?
|
Octreotide | 1 | 2005 | 155 | 0.240 |
Why?
|
Neutropenia | 4 | 2023 | 893 | 0.230 |
Why?
|
Terminal Care | 3 | 2023 | 1772 | 0.230 |
Why?
|
Clinical Trials as Topic | 6 | 2024 | 8055 | 0.230 |
Why?
|
Diarrhea | 5 | 2019 | 1320 | 0.230 |
Why?
|
Leukemia, Myeloid | 3 | 1996 | 693 | 0.220 |
Why?
|
Membrane Proteins | 7 | 2020 | 7885 | 0.220 |
Why?
|
Polyethylene Glycols | 4 | 2024 | 1197 | 0.220 |
Why?
|
High-Throughput Nucleotide Sequencing | 4 | 2020 | 3671 | 0.220 |
Why?
|
Adenosine Diphosphate Ribose | 1 | 2023 | 70 | 0.210 |
Why?
|
RNA, Satellite | 1 | 2022 | 16 | 0.210 |
Why?
|
Ribose | 1 | 2022 | 63 | 0.210 |
Why?
|
Feasibility Studies | 6 | 2024 | 5323 | 0.200 |
Why?
|
Diphosphates | 1 | 2022 | 89 | 0.200 |
Why?
|
Telemedicine | 4 | 2024 | 3110 | 0.200 |
Why?
|
Genomics | 5 | 2020 | 5928 | 0.200 |
Why?
|
Cell Line, Tumor | 16 | 2024 | 17173 | 0.200 |
Why?
|
Survival Analysis | 12 | 2019 | 10115 | 0.200 |
Why?
|
Tumor Microenvironment | 7 | 2023 | 3952 | 0.200 |
Why?
|
Anemia | 5 | 2018 | 1517 | 0.200 |
Why?
|
Vulvar Neoplasms | 2 | 2016 | 266 | 0.190 |
Why?
|
DNA Replication | 4 | 2021 | 1428 | 0.190 |
Why?
|
Hospice Care | 2 | 2023 | 679 | 0.190 |
Why?
|
Phosphatidylinositol 3-Kinases | 5 | 2022 | 2884 | 0.190 |
Why?
|
Health Services for the Aged | 1 | 2004 | 264 | 0.190 |
Why?
|
Neoplastic Syndromes, Hereditary | 1 | 2023 | 249 | 0.190 |
Why?
|
MicroRNAs | 4 | 2021 | 3811 | 0.180 |
Why?
|
Ovariectomy | 3 | 2020 | 613 | 0.180 |
Why?
|
Young Adult | 15 | 2024 | 60131 | 0.180 |
Why?
|
Class I Phosphatidylinositol 3-Kinases | 3 | 2023 | 906 | 0.180 |
Why?
|
Caregivers | 4 | 2024 | 2308 | 0.180 |
Why?
|
Ascites | 2 | 2020 | 338 | 0.180 |
Why?
|
Adaptation, Psychological | 3 | 2013 | 2666 | 0.180 |
Why?
|
Aniline Compounds | 2 | 2024 | 1095 | 0.180 |
Why?
|
Cohort Studies | 14 | 2021 | 41808 | 0.180 |
Why?
|
Mass Screening | 1 | 2016 | 5457 | 0.180 |
Why?
|
Pilot Projects | 10 | 2024 | 8748 | 0.170 |
Why?
|
Gene Amplification | 3 | 2020 | 1099 | 0.170 |
Why?
|
Single-Cell Analysis | 3 | 2020 | 2542 | 0.170 |
Why?
|
Acupuncture Therapy | 3 | 2010 | 486 | 0.170 |
Why?
|
Apoptosis | 6 | 2020 | 9527 | 0.170 |
Why?
|
Infusions, Parenteral | 3 | 2021 | 396 | 0.170 |
Why?
|
Time Factors | 14 | 2020 | 40261 | 0.170 |
Why?
|
Animals | 30 | 2024 | 169335 | 0.170 |
Why?
|
Cystadenoma, Serous | 1 | 2020 | 100 | 0.170 |
Why?
|
Neuroglia | 1 | 2005 | 960 | 0.170 |
Why?
|
Neoadjuvant Therapy | 6 | 2022 | 2909 | 0.160 |
Why?
|
Nomograms | 1 | 2021 | 236 | 0.160 |
Why?
|
Proportional Hazards Models | 8 | 2018 | 12562 | 0.160 |
Why?
|
Follow-Up Studies | 9 | 2020 | 39394 | 0.160 |
Why?
|
Diamines | 1 | 2019 | 60 | 0.160 |
Why?
|
Mullerian Ducts | 2 | 2019 | 203 | 0.160 |
Why?
|
Cystadenocarcinoma, Papillary | 2 | 2012 | 56 | 0.160 |
Why?
|
Immunohistochemistry | 7 | 2020 | 11116 | 0.160 |
Why?
|
Portraits as Topic | 1 | 2018 | 32 | 0.160 |
Why?
|
Phenylenediamines | 1 | 2018 | 89 | 0.150 |
Why?
|
Multicenter Studies as Topic | 2 | 2022 | 1737 | 0.150 |
Why?
|
Pelvic Neoplasms | 1 | 2020 | 250 | 0.150 |
Why?
|
Prospective Studies | 16 | 2022 | 54962 | 0.150 |
Why?
|
CDC2 Protein Kinase | 1 | 2018 | 212 | 0.150 |
Why?
|
MAP Kinase Kinase Kinases | 1 | 2019 | 252 | 0.150 |
Why?
|
Disease Progression | 8 | 2020 | 13674 | 0.140 |
Why?
|
Killer Cells, Natural | 2 | 2024 | 2211 | 0.140 |
Why?
|
Nausea | 3 | 2018 | 682 | 0.140 |
Why?
|
Granulocyte Colony-Stimulating Factor | 4 | 2006 | 631 | 0.140 |
Why?
|
Capsules | 2 | 2018 | 193 | 0.140 |
Why?
|
5-Methylcytosine | 1 | 2017 | 147 | 0.140 |
Why?
|
Receptor-Interacting Protein Serine-Threonine Kinases | 1 | 2018 | 146 | 0.140 |
Why?
|
Ophthalmic Solutions | 1 | 2018 | 312 | 0.140 |
Why?
|
Proto-Oncogene Proteins c-akt | 2 | 2019 | 2460 | 0.140 |
Why?
|
Microsatellite Instability | 2 | 2023 | 726 | 0.140 |
Why?
|
Heterocyclic Compounds, 3-Ring | 1 | 2019 | 296 | 0.140 |
Why?
|
Gene Fusion | 1 | 2019 | 357 | 0.140 |
Why?
|
Complementary Therapies | 2 | 2013 | 487 | 0.140 |
Why?
|
Radiation Tolerance | 1 | 2019 | 478 | 0.140 |
Why?
|
Cyclophosphamide | 3 | 2012 | 2227 | 0.140 |
Why?
|
Genetic Counseling | 1 | 2020 | 634 | 0.140 |
Why?
|
Signal Transduction | 8 | 2020 | 23653 | 0.130 |
Why?
|
Sterilization, Tubal | 1 | 2016 | 78 | 0.130 |
Why?
|
Tumor Cells, Cultured | 8 | 2020 | 6131 | 0.130 |
Why?
|
Proto-Oncogene Proteins p21(ras) | 1 | 2024 | 1769 | 0.130 |
Why?
|
Retrospective Studies | 18 | 2024 | 81903 | 0.130 |
Why?
|
DNA Mutational Analysis | 5 | 2020 | 4124 | 0.130 |
Why?
|
Leukemia, Experimental | 1 | 1996 | 225 | 0.130 |
Why?
|
Thrombocytopenia | 3 | 2024 | 1181 | 0.130 |
Why?
|
Fusion Proteins, bcr-abl | 3 | 1995 | 430 | 0.130 |
Why?
|
Antibodies, Anti-Idiotypic | 1 | 2016 | 355 | 0.120 |
Why?
|
Epigenesis, Genetic | 2 | 2019 | 3836 | 0.120 |
Why?
|
Contraceptives, Oral, Hormonal | 1 | 2016 | 190 | 0.120 |
Why?
|
Mice | 21 | 2024 | 82072 | 0.120 |
Why?
|
Cyclin-Dependent Kinases | 1 | 2018 | 664 | 0.120 |
Why?
|
DNA Copy Number Variations | 4 | 2020 | 2055 | 0.120 |
Why?
|
Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 3 | 2015 | 686 | 0.120 |
Why?
|
Skin Tests | 4 | 2015 | 639 | 0.120 |
Why?
|
Nanoparticles | 2 | 2017 | 1989 | 0.120 |
Why?
|
Carcinoma, Squamous Cell | 3 | 2016 | 4064 | 0.110 |
Why?
|
Proto-Oncogene Proteins c-bcl-2 | 2 | 2019 | 1408 | 0.110 |
Why?
|
Acetaminophen | 1 | 2018 | 556 | 0.110 |
Why?
|
Apoptosis Regulatory Proteins | 1 | 2019 | 1151 | 0.110 |
Why?
|
Legionellosis | 1 | 1993 | 11 | 0.110 |
Why?
|
Protein-Tyrosine Kinases | 2 | 2021 | 2433 | 0.110 |
Why?
|
Blood Transfusion, Autologous | 1 | 1994 | 130 | 0.110 |
Why?
|
Benzoquinones | 1 | 2014 | 198 | 0.110 |
Why?
|
Legionnaires' Disease | 1 | 1993 | 50 | 0.110 |
Why?
|
Gynecologic Surgical Procedures | 1 | 2016 | 289 | 0.110 |
Why?
|
Drug Evaluation, Preclinical | 1 | 2018 | 1340 | 0.110 |
Why?
|
Decontamination | 1 | 1993 | 73 | 0.110 |
Why?
|
Parity | 1 | 2016 | 931 | 0.110 |
Why?
|
Proto-Oncogene Proteins c-myc | 1 | 2018 | 998 | 0.110 |
Why?
|
Tablets | 1 | 2013 | 149 | 0.100 |
Why?
|
Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2016 | 710 | 0.100 |
Why?
|
Water Microbiology | 1 | 1993 | 117 | 0.100 |
Why?
|
Oncogenes | 2 | 2021 | 1236 | 0.100 |
Why?
|
Immunologic Factors | 1 | 2022 | 1597 | 0.100 |
Why?
|
Immunity | 1 | 2018 | 1003 | 0.100 |
Why?
|
Proto-Oncogene Proteins | 4 | 2018 | 4528 | 0.100 |
Why?
|
Sickness Impact Profile | 2 | 2013 | 299 | 0.100 |
Why?
|
Risk Assessment | 6 | 2019 | 24333 | 0.100 |
Why?
|
Melphalan | 1 | 1994 | 421 | 0.100 |
Why?
|
Lactams, Macrocyclic | 1 | 2014 | 319 | 0.100 |
Why?
|
Hydroxamic Acids | 1 | 2015 | 483 | 0.100 |
Why?
|
Folate Receptors, GPI-Anchored | 1 | 2012 | 23 | 0.100 |
Why?
|
Interleukin-3 | 1 | 1993 | 425 | 0.100 |
Why?
|
Rabbits | 1 | 2018 | 4774 | 0.100 |
Why?
|
Placebos | 1 | 2016 | 1667 | 0.100 |
Why?
|
Cell Death | 2 | 2015 | 1682 | 0.100 |
Why?
|
Organoids | 1 | 2018 | 745 | 0.100 |
Why?
|
Cytarabine | 1 | 1994 | 697 | 0.100 |
Why?
|
Proteinuria | 2 | 2018 | 610 | 0.100 |
Why?
|
Genome, Human | 2 | 2019 | 4456 | 0.100 |
Why?
|
Adenocarcinoma | 3 | 2019 | 6401 | 0.100 |
Why?
|
Neovascularization, Pathologic | 2 | 2012 | 2634 | 0.100 |
Why?
|
Endpoint Determination | 1 | 2014 | 594 | 0.100 |
Why?
|
Ovary | 3 | 2020 | 965 | 0.100 |
Why?
|
Intestinal Perforation | 2 | 2018 | 254 | 0.100 |
Why?
|
Analgesics | 1 | 2018 | 1071 | 0.090 |
Why?
|
Cell Nucleus | 1 | 2020 | 2885 | 0.090 |
Why?
|
Medical Oncology | 3 | 2020 | 2350 | 0.090 |
Why?
|
Cornea | 1 | 2018 | 1315 | 0.090 |
Why?
|
Antineoplastic Agents, Alkylating | 2 | 2005 | 618 | 0.090 |
Why?
|
Receptor Protein-Tyrosine Kinases | 1 | 2018 | 1629 | 0.090 |
Why?
|
Mice, Nude | 4 | 2020 | 3631 | 0.090 |
Why?
|
Myelodysplastic Syndromes | 1 | 2021 | 1399 | 0.090 |
Why?
|
Pain | 1 | 2005 | 5100 | 0.090 |
Why?
|
Risk Factors | 12 | 2022 | 74976 | 0.090 |
Why?
|
Neoplasm Invasiveness | 4 | 2018 | 3629 | 0.090 |
Why?
|
Decision Making | 1 | 2024 | 3953 | 0.090 |
Why?
|
Tumor Suppressor Protein p53 | 2 | 2020 | 2960 | 0.090 |
Why?
|
Patient Compliance | 1 | 2020 | 2701 | 0.090 |
Why?
|
Poly Adenosine Diphosphate Ribose | 1 | 2010 | 51 | 0.090 |
Why?
|
Vinblastine | 3 | 2001 | 487 | 0.090 |
Why?
|
Elafin | 1 | 2010 | 30 | 0.090 |
Why?
|
Papillomaviridae | 1 | 2016 | 1140 | 0.090 |
Why?
|
Pancreatic Neoplasms | 2 | 2019 | 5443 | 0.090 |
Why?
|
Inflammatory Breast Neoplasms | 1 | 2012 | 154 | 0.080 |
Why?
|
Drug Synergism | 3 | 2019 | 1762 | 0.080 |
Why?
|
Hematinics | 3 | 2012 | 282 | 0.080 |
Why?
|
Neoplasm, Residual | 3 | 2023 | 1019 | 0.080 |
Why?
|
Bone Marrow Cells | 2 | 1995 | 2414 | 0.080 |
Why?
|
Cell Cycle Proteins | 1 | 2021 | 3450 | 0.080 |
Why?
|
Heterozygote | 2 | 2013 | 2798 | 0.080 |
Why?
|
Matrix Metalloproteinase 2 | 1 | 2011 | 462 | 0.080 |
Why?
|
beta Catenin | 1 | 2014 | 1047 | 0.080 |
Why?
|
Antigen-Antibody Complex | 1 | 2010 | 513 | 0.080 |
Why?
|
Confidence Intervals | 1 | 2014 | 2932 | 0.080 |
Why?
|
Antibiotics, Antineoplastic | 2 | 2024 | 682 | 0.080 |
Why?
|
HLA-D Antigens | 1 | 2008 | 130 | 0.080 |
Why?
|
Receptor, erbB-3 | 1 | 2009 | 143 | 0.080 |
Why?
|
Patient-Centered Care | 1 | 2019 | 1447 | 0.080 |
Why?
|
Reoperation | 1 | 2019 | 4342 | 0.080 |
Why?
|
Paraffin Embedding | 1 | 2009 | 306 | 0.080 |
Why?
|
Tissue Fixation | 1 | 2009 | 245 | 0.080 |
Why?
|
Neoplasm Transplantation | 3 | 2018 | 2018 | 0.080 |
Why?
|
Benzimidazoles | 1 | 2014 | 864 | 0.080 |
Why?
|
Stomach Neoplasms | 1 | 2019 | 1483 | 0.080 |
Why?
|
Proto-Oncogene Proteins B-raf | 1 | 2018 | 2059 | 0.080 |
Why?
|
Long Interspersed Nucleotide Elements | 2 | 2023 | 332 | 0.080 |
Why?
|
Adolescent | 10 | 2020 | 89244 | 0.080 |
Why?
|
Anti-Inflammatory Agents, Non-Steroidal | 1 | 2018 | 2276 | 0.080 |
Why?
|
Bone Marrow | 4 | 2016 | 2936 | 0.080 |
Why?
|
Omentum | 2 | 2019 | 168 | 0.080 |
Why?
|
Neoplastic Stem Cells | 2 | 2012 | 1356 | 0.080 |
Why?
|
Formaldehyde | 1 | 2009 | 361 | 0.070 |
Why?
|
Matrix Metalloproteinase 9 | 1 | 2011 | 633 | 0.070 |
Why?
|
Sequence Analysis, RNA | 3 | 2020 | 2041 | 0.070 |
Why?
|
Granulocyte-Macrophage Colony-Stimulating Factor | 2 | 2009 | 892 | 0.070 |
Why?
|
Smoking Cessation | 1 | 2019 | 2085 | 0.070 |
Why?
|
Receptors, Notch | 1 | 2012 | 751 | 0.070 |
Why?
|
Predictive Value of Tests | 5 | 2020 | 15471 | 0.070 |
Why?
|
Psychological Tests | 1 | 2010 | 642 | 0.070 |
Why?
|
T-Lymphocytes, Cytotoxic | 2 | 2018 | 1803 | 0.070 |
Why?
|
Guanine | 1 | 2008 | 280 | 0.070 |
Why?
|
Glutamates | 1 | 2008 | 385 | 0.070 |
Why?
|
Disease Management | 1 | 2018 | 2537 | 0.070 |
Why?
|
Early Detection of Cancer | 3 | 2016 | 3238 | 0.070 |
Why?
|
Hedgehog Proteins | 1 | 2012 | 771 | 0.070 |
Why?
|
Exanthema | 1 | 2012 | 503 | 0.070 |
Why?
|
DNA Primers | 1 | 2011 | 2827 | 0.070 |
Why?
|
Brachytherapy | 2 | 2012 | 1224 | 0.070 |
Why?
|
Hypertension | 3 | 2019 | 8617 | 0.070 |
Why?
|
Leukemia, Myeloid, Acute | 2 | 2021 | 3626 | 0.070 |
Why?
|
Ubiquitin-Protein Ligases | 1 | 2016 | 1902 | 0.070 |
Why?
|
Advance Care Planning | 2 | 2024 | 698 | 0.070 |
Why?
|
Algorithms | 3 | 2020 | 14201 | 0.070 |
Why?
|
Aspirin | 1 | 2018 | 3135 | 0.070 |
Why?
|
Severity of Illness Index | 4 | 2015 | 15951 | 0.070 |
Why?
|
Multivariate Analysis | 4 | 2016 | 12095 | 0.070 |
Why?
|
Antineoplastic Agents, Hormonal | 2 | 2005 | 1535 | 0.070 |
Why?
|
Leukopenia | 1 | 2007 | 212 | 0.070 |
Why?
|
Infection Control | 1 | 1993 | 985 | 0.070 |
Why?
|
Data Interpretation, Statistical | 1 | 2016 | 2714 | 0.060 |
Why?
|
Pyrroles | 1 | 2012 | 1125 | 0.060 |
Why?
|
CD8-Positive T-Lymphocytes | 4 | 2022 | 4651 | 0.060 |
Why?
|
Motivation | 2 | 2021 | 2025 | 0.060 |
Why?
|
RNA, Messenger | 2 | 2012 | 12806 | 0.060 |
Why?
|
Hospices | 2 | 2010 | 245 | 0.060 |
Why?
|
Lymphatic Metastasis | 1 | 2013 | 2916 | 0.060 |
Why?
|
Needs Assessment | 1 | 2012 | 1143 | 0.060 |
Why?
|
Bone Marrow Transplantation | 1 | 1993 | 2709 | 0.060 |
Why?
|
Cell Adhesion | 1 | 2012 | 3102 | 0.060 |
Why?
|
Antigens, CD | 1 | 1996 | 4032 | 0.060 |
Why?
|
Membrane Glycoproteins | 1 | 1996 | 3713 | 0.060 |
Why?
|
Alleles | 2 | 2017 | 6901 | 0.060 |
Why?
|
Disease Models, Animal | 4 | 2018 | 18354 | 0.060 |
Why?
|
Diagnosis, Differential | 1 | 2020 | 13021 | 0.060 |
Why?
|
Proteins | 3 | 2023 | 6011 | 0.060 |
Why?
|
Sesquiterpenes | 1 | 2005 | 177 | 0.060 |
Why?
|
Statistics, Nonparametric | 2 | 2019 | 2862 | 0.060 |
Why?
|
Urokinase-Type Plasminogen Activator | 1 | 2005 | 324 | 0.060 |
Why?
|
Mitochondria | 3 | 2015 | 3682 | 0.060 |
Why?
|
Drug Industry | 1 | 2011 | 793 | 0.060 |
Why?
|
Mice, Inbred C3H | 2 | 1996 | 915 | 0.060 |
Why?
|
Drug Approval | 1 | 2011 | 821 | 0.060 |
Why?
|
Sexual Dysfunction, Physiological | 1 | 2008 | 365 | 0.060 |
Why?
|
Mass Spectrometry | 1 | 2011 | 2204 | 0.060 |
Why?
|
Lymphocyte Activation | 1 | 1995 | 5505 | 0.060 |
Why?
|
Diet | 1 | 2022 | 8088 | 0.060 |
Why?
|
Aryl Hydrocarbon Hydroxylases | 1 | 2005 | 246 | 0.060 |
Why?
|
Exercise | 1 | 2021 | 5954 | 0.060 |
Why?
|
Gene Dosage | 2 | 2020 | 1222 | 0.060 |
Why?
|
Extracellular Matrix | 1 | 2012 | 1739 | 0.060 |
Why?
|
Erythropoietin | 2 | 2008 | 718 | 0.060 |
Why?
|
Dioxoles | 1 | 2004 | 96 | 0.060 |
Why?
|
Colorectal Neoplasms | 1 | 2023 | 6982 | 0.060 |
Why?
|
Epithelial-Mesenchymal Transition | 2 | 2022 | 755 | 0.060 |
Why?
|
Topoisomerase I Inhibitors | 1 | 2023 | 70 | 0.050 |
Why?
|
Genotype | 3 | 2013 | 13048 | 0.050 |
Why?
|
Patient Preference | 1 | 2010 | 947 | 0.050 |
Why?
|
Ammonia | 1 | 2023 | 248 | 0.050 |
Why?
|
GPI-Linked Proteins | 1 | 2024 | 472 | 0.050 |
Why?
|
Intensive Care Units | 2 | 2010 | 3800 | 0.050 |
Why?
|
Dehydration | 1 | 2004 | 216 | 0.050 |
Why?
|
Isoquinolines | 1 | 2004 | 354 | 0.050 |
Why?
|
Disability Evaluation | 1 | 2010 | 1839 | 0.050 |
Why?
|
Coronavirus Infections | 1 | 2020 | 3118 | 0.050 |
Why?
|
Clinical Protocols | 1 | 2008 | 1445 | 0.050 |
Why?
|
Male | 21 | 2024 | 365203 | 0.050 |
Why?
|
Pneumonia, Viral | 1 | 2020 | 3241 | 0.050 |
Why?
|
Sexual Behavior | 1 | 2012 | 2200 | 0.050 |
Why?
|
Europe | 3 | 2019 | 3441 | 0.050 |
Why?
|
Mice, SCID | 2 | 2018 | 2631 | 0.050 |
Why?
|
NF-kappa B | 1 | 2010 | 2492 | 0.050 |
Why?
|
Emotions | 1 | 2013 | 2768 | 0.050 |
Why?
|
Retinoblastoma Binding Proteins | 1 | 2021 | 101 | 0.050 |
Why?
|
Genetic Predisposition to Disease | 3 | 2020 | 18068 | 0.050 |
Why?
|
Antigens, Neoplasm | 3 | 2016 | 2001 | 0.050 |
Why?
|
Gastrointestinal Agents | 1 | 2005 | 510 | 0.040 |
Why?
|
GTP Phosphohydrolases | 1 | 2024 | 524 | 0.040 |
Why?
|
Age of Onset | 1 | 2008 | 3346 | 0.040 |
Why?
|
Immunotherapy, Adoptive | 2 | 2024 | 1520 | 0.040 |
Why?
|
Albumins | 1 | 2023 | 577 | 0.040 |
Why?
|
Activities of Daily Living | 1 | 2010 | 2434 | 0.040 |
Why?
|
Neoplasm Metastasis | 6 | 2017 | 4926 | 0.040 |
Why?
|
Radiotherapy, Adjuvant | 1 | 2005 | 1793 | 0.040 |
Why?
|
Patient Acceptance of Health Care | 2 | 2024 | 3235 | 0.040 |
Why?
|
Janus Kinase 1 | 1 | 2020 | 108 | 0.040 |
Why?
|
Psychometrics | 1 | 2010 | 3066 | 0.040 |
Why?
|
In Situ Hybridization, Fluorescence | 2 | 2020 | 2525 | 0.040 |
Why?
|
Pandemics | 1 | 2020 | 8749 | 0.040 |
Why?
|
Self Efficacy | 1 | 2024 | 643 | 0.040 |
Why?
|
Rad51 Recombinase | 1 | 2020 | 191 | 0.040 |
Why?
|
Vision Disorders | 2 | 2017 | 1093 | 0.040 |
Why?
|
STAT Transcription Factors | 1 | 2020 | 189 | 0.040 |
Why?
|
Adnexa Uteri | 1 | 2019 | 40 | 0.040 |
Why?
|
Referral and Consultation | 2 | 2020 | 3628 | 0.040 |
Why?
|
Freezing | 1 | 2020 | 311 | 0.040 |
Why?
|
Boston | 2 | 2010 | 9377 | 0.040 |
Why?
|
Phenotype | 3 | 2024 | 16731 | 0.040 |
Why?
|
HSP90 Heat-Shock Proteins | 1 | 2021 | 423 | 0.040 |
Why?
|
STAT3 Transcription Factor | 1 | 2023 | 874 | 0.040 |
Why?
|
Nitriles | 1 | 2003 | 990 | 0.040 |
Why?
|
Online Systems | 1 | 2019 | 182 | 0.040 |
Why?
|
Age Factors | 3 | 2013 | 18435 | 0.040 |
Why?
|
Immunoglobulin E | 1 | 2004 | 1506 | 0.040 |
Why?
|
eIF-2 Kinase | 1 | 2019 | 147 | 0.040 |
Why?
|
T-Lymphocytes | 1 | 1996 | 10276 | 0.040 |
Why?
|
Triazoles | 1 | 2003 | 904 | 0.040 |
Why?
|
Clinical Trials, Phase I as Topic | 1 | 2019 | 330 | 0.040 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 3 | 2010 | 4592 | 0.040 |
Why?
|
Azacitidine | 1 | 2019 | 336 | 0.040 |
Why?
|
Guidelines as Topic | 1 | 2004 | 1399 | 0.040 |
Why?
|
Societies, Scientific | 1 | 2019 | 223 | 0.040 |
Why?
|
Blood Transfusion | 3 | 2012 | 1309 | 0.040 |
Why?
|
Cancer Vaccines | 1 | 2005 | 1043 | 0.040 |
Why?
|
Peptide Fragments | 2 | 2011 | 5151 | 0.040 |
Why?
|
Mice, Inbred BALB C | 2 | 2017 | 6232 | 0.040 |
Why?
|
X-Linked Inhibitor of Apoptosis Protein | 1 | 2017 | 61 | 0.040 |
Why?
|
Immunologic Memory | 1 | 2024 | 1378 | 0.040 |
Why?
|
Fluorescent Antibody Technique | 2 | 2014 | 2474 | 0.040 |
Why?
|
Mast Cells | 1 | 2004 | 1406 | 0.040 |
Why?
|
Polymorphism, Single Nucleotide | 2 | 2017 | 16053 | 0.040 |
Why?
|
Epistaxis | 1 | 2018 | 117 | 0.030 |
Why?
|
Benchmarking | 1 | 2023 | 1059 | 0.030 |
Why?
|
Epithelium | 2 | 2014 | 1607 | 0.030 |
Why?
|
Water-Electrolyte Imbalance | 1 | 2018 | 111 | 0.030 |
Why?
|
Macrophages | 2 | 2023 | 5801 | 0.030 |
Why?
|
Medical History Taking | 1 | 2020 | 779 | 0.030 |
Why?
|
Health Status | 1 | 2010 | 4095 | 0.030 |
Why?
|
Gastrointestinal Neoplasms | 1 | 2024 | 957 | 0.030 |
Why?
|
Transfection | 2 | 1995 | 5763 | 0.030 |
Why?
|
Hypophosphatemia | 1 | 2017 | 93 | 0.030 |
Why?
|
Cell Line | 3 | 2015 | 15604 | 0.030 |
Why?
|
Nursing Homes | 1 | 2004 | 1084 | 0.030 |
Why?
|
Injections, Subcutaneous | 2 | 2009 | 687 | 0.030 |
Why?
|
Organ Culture Techniques | 1 | 2018 | 796 | 0.030 |
Why?
|
Interferons | 1 | 2020 | 720 | 0.030 |
Why?
|
Intercellular Signaling Peptides and Proteins | 1 | 2023 | 1658 | 0.030 |
Why?
|
Hematopoietic Stem Cell Transplantation | 1 | 1994 | 5716 | 0.030 |
Why?
|
Platelet Count | 1 | 2018 | 787 | 0.030 |
Why?
|
Dioxygenases | 1 | 2017 | 352 | 0.030 |
Why?
|
Antigens, Nuclear | 1 | 2016 | 183 | 0.030 |
Why?
|
Socioeconomic Factors | 1 | 2009 | 7861 | 0.030 |
Why?
|
Microtubule-Associated Proteins | 1 | 2020 | 1074 | 0.030 |
Why?
|
Soft Tissue Neoplasms | 1 | 2004 | 1166 | 0.030 |
Why?
|
Retreatment | 1 | 2016 | 600 | 0.030 |
Why?
|
Immunocompetence | 1 | 1995 | 138 | 0.030 |
Why?
|
Injections, Intraperitoneal | 1 | 2015 | 412 | 0.030 |
Why?
|
Data Mining | 1 | 2020 | 563 | 0.030 |
Why?
|
Biopsy | 2 | 2020 | 6805 | 0.030 |
Why?
|
Blotting, Western | 2 | 2014 | 5033 | 0.030 |
Why?
|
RNA Interference | 2 | 2016 | 2835 | 0.030 |
Why?
|
Vomiting | 1 | 2018 | 655 | 0.030 |
Why?
|
Hodgkin Disease | 1 | 2002 | 1384 | 0.030 |
Why?
|
Neoplasms, Second Primary | 1 | 2002 | 1060 | 0.030 |
Why?
|
Flow Cytometry | 2 | 2015 | 5906 | 0.030 |
Why?
|
Necrosis | 1 | 2018 | 1620 | 0.030 |
Why?
|
Keratitis | 1 | 2017 | 241 | 0.030 |
Why?
|
Congresses as Topic | 1 | 2019 | 812 | 0.030 |
Why?
|
Drug Monitoring | 1 | 2020 | 965 | 0.030 |
Why?
|
Legionella | 1 | 1993 | 27 | 0.030 |
Why?
|
Cell Line, Transformed | 1 | 1995 | 867 | 0.030 |
Why?
|
Systems Biology | 1 | 2017 | 482 | 0.030 |
Why?
|
Canada | 1 | 2019 | 2130 | 0.030 |
Why?
|
Oligonucleotides, Antisense | 1 | 2016 | 461 | 0.030 |
Why?
|
Qualitative Research | 1 | 2024 | 3143 | 0.030 |
Why?
|
Observer Variation | 1 | 2019 | 2623 | 0.030 |
Why?
|
Suicide | 1 | 2004 | 1606 | 0.030 |
Why?
|
Sarcoma | 1 | 2004 | 1806 | 0.030 |
Why?
|
Genes, erbB-1 | 1 | 2013 | 163 | 0.030 |
Why?
|
RNA | 1 | 2022 | 2727 | 0.030 |
Why?
|
Protein Array Analysis | 1 | 2014 | 400 | 0.030 |
Why?
|
Mice, Knockout | 2 | 2020 | 14484 | 0.030 |
Why?
|
Up-Regulation | 1 | 2021 | 4148 | 0.030 |
Why?
|
Spheroids, Cellular | 1 | 2014 | 331 | 0.020 |
Why?
|
Forkhead Transcription Factors | 1 | 2019 | 1625 | 0.020 |
Why?
|
Water Supply | 1 | 1993 | 204 | 0.020 |
Why?
|
Filgrastim | 2 | 2005 | 131 | 0.020 |
Why?
|
Pennsylvania | 1 | 1993 | 615 | 0.020 |
Why?
|
Graft Rejection | 2 | 1996 | 4492 | 0.020 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 2 | 2011 | 3813 | 0.020 |
Why?
|
Mitogen-Activated Protein Kinase 1 | 1 | 1993 | 478 | 0.020 |
Why?
|
MAP Kinase Signaling System | 1 | 2019 | 1495 | 0.020 |
Why?
|
Sequence Alignment | 1 | 2016 | 2179 | 0.020 |
Why?
|
Etoposide | 2 | 2005 | 639 | 0.020 |
Why?
|
Protein Kinases | 1 | 2018 | 1611 | 0.020 |
Why?
|
Paired Box Transcription Factors | 1 | 2012 | 206 | 0.020 |
Why?
|
Propensity Score | 1 | 2019 | 1968 | 0.020 |
Why?
|
Down-Regulation | 1 | 2018 | 2942 | 0.020 |
Why?
|
Incidence | 2 | 2021 | 21547 | 0.020 |
Why?
|
Practice Guidelines as Topic | 2 | 2020 | 7460 | 0.020 |
Why?
|
Immunoenzyme Techniques | 1 | 2014 | 1705 | 0.020 |
Why?
|
Cell Proliferation | 2 | 2020 | 10486 | 0.020 |
Why?
|
Mesoderm | 1 | 2014 | 679 | 0.020 |
Why?
|
Leukemia, Myelomonocytic, Acute | 1 | 1990 | 38 | 0.020 |
Why?
|
Histocytochemistry | 1 | 2012 | 699 | 0.020 |
Why?
|
Leukemia, Monocytic, Acute | 1 | 1990 | 58 | 0.020 |
Why?
|
Oligonucleotide Array Sequence Analysis | 2 | 2009 | 3810 | 0.020 |
Why?
|
Hypotension | 1 | 2016 | 888 | 0.020 |
Why?
|
Lipocalins | 1 | 2011 | 161 | 0.020 |
Why?
|
Membrane Potential, Mitochondrial | 1 | 2011 | 297 | 0.020 |
Why?
|
Case-Control Studies | 2 | 2021 | 22296 | 0.020 |
Why?
|
Acute-Phase Proteins | 1 | 2011 | 252 | 0.020 |
Why?
|
Attitude of Health Personnel | 1 | 2004 | 3928 | 0.020 |
Why?
|
DNA Breaks, Double-Stranded | 1 | 2015 | 608 | 0.020 |
Why?
|
Postoperative Period | 1 | 2015 | 1830 | 0.020 |
Why?
|
Headache | 1 | 2018 | 1264 | 0.020 |
Why?
|
Depression | 2 | 2013 | 8231 | 0.020 |
Why?
|
Hysterectomy | 1 | 2015 | 866 | 0.020 |
Why?
|
Health Status Disparities | 1 | 2021 | 1886 | 0.020 |
Why?
|
Fibroblasts | 1 | 2020 | 4179 | 0.020 |
Why?
|
Permeability | 1 | 2011 | 726 | 0.020 |
Why?
|
Gene Knockdown Techniques | 1 | 2014 | 1608 | 0.020 |
Why?
|
DNA-Binding Proteins | 2 | 2017 | 9618 | 0.020 |
Why?
|
HEK293 Cells | 1 | 2018 | 4290 | 0.020 |
Why?
|
United States | 4 | 2019 | 73186 | 0.020 |
Why?
|
DNA, Viral | 1 | 2016 | 2205 | 0.020 |
Why?
|
Frozen Sections | 1 | 2009 | 154 | 0.020 |
Why?
|
Recombinant Proteins | 3 | 2005 | 6512 | 0.020 |
Why?
|
Transplantation, Autologous | 1 | 1994 | 2126 | 0.020 |
Why?
|
Lymph Node Excision | 1 | 2015 | 1273 | 0.020 |
Why?
|
Liposomes | 2 | 2004 | 793 | 0.020 |
Why?
|
Repressor Proteins | 1 | 2019 | 2986 | 0.020 |
Why?
|
Radiotherapy, Intensity-Modulated | 1 | 2015 | 812 | 0.020 |
Why?
|
Logistic Models | 2 | 2015 | 13318 | 0.020 |
Why?
|
Spirituality | 1 | 2013 | 430 | 0.020 |
Why?
|
Patient Selection | 1 | 2020 | 4265 | 0.020 |
Why?
|
TOR Serine-Threonine Kinases | 1 | 2017 | 2063 | 0.020 |
Why?
|
Phosphorylation | 3 | 1994 | 8317 | 0.020 |
Why?
|
Chronic Disease | 1 | 2023 | 9384 | 0.020 |
Why?
|
Blotting, Northern | 1 | 2010 | 1553 | 0.020 |
Why?
|
Tissue Array Analysis | 1 | 2010 | 551 | 0.020 |
Why?
|
SEER Program | 1 | 2013 | 1473 | 0.020 |
Why?
|
Neoplasm Proteins | 1 | 2020 | 3608 | 0.020 |
Why?
|
Computational Biology | 1 | 2020 | 3562 | 0.020 |
Why?
|
Cell Differentiation | 1 | 2005 | 11684 | 0.020 |
Why?
|
Reproducibility of Results | 2 | 2020 | 20245 | 0.020 |
Why?
|
Cell Survival | 1 | 2017 | 5793 | 0.020 |
Why?
|
Tyrosine | 1 | 1992 | 1427 | 0.020 |
Why?
|
Carcinosarcoma | 1 | 2008 | 108 | 0.020 |
Why?
|
RNA Stability | 1 | 2009 | 321 | 0.020 |
Why?
|
Body Weight | 1 | 2018 | 4628 | 0.020 |
Why?
|
Cancer Care Facilities | 1 | 2010 | 428 | 0.020 |
Why?
|
Abdomen | 1 | 2013 | 1137 | 0.020 |
Why?
|
Dendritic Cells | 1 | 2018 | 2748 | 0.020 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 2 | 2017 | 5434 | 0.020 |
Why?
|
Area Under Curve | 1 | 2011 | 1645 | 0.020 |
Why?
|
Chromatin Immunoprecipitation | 1 | 2010 | 859 | 0.020 |
Why?
|
Chromosome Aberrations | 1 | 2013 | 1780 | 0.020 |
Why?
|
Vagina | 1 | 2012 | 849 | 0.020 |
Why?
|
Mice, Inbred C57BL | 2 | 2018 | 22379 | 0.020 |
Why?
|
RNA, Neoplasm | 1 | 2009 | 751 | 0.020 |
Why?
|
Microscopy | 1 | 2012 | 910 | 0.020 |
Why?
|
Second-Look Surgery | 1 | 2006 | 27 | 0.020 |
Why?
|
Recombinant Fusion Proteins | 1 | 1995 | 3744 | 0.020 |
Why?
|
Ferric Compounds | 1 | 2008 | 376 | 0.020 |
Why?
|
Gene Frequency | 1 | 2013 | 3626 | 0.020 |
Why?
|
Drugs, Generic | 1 | 2011 | 455 | 0.020 |
Why?
|
Genes, erbB-2 | 1 | 2006 | 162 | 0.020 |
Why?
|
Death | 1 | 2010 | 683 | 0.020 |
Why?
|
Hemorrhage | 1 | 2018 | 3466 | 0.020 |
Why?
|
Remission Induction | 1 | 2011 | 2408 | 0.020 |
Why?
|
Autoimmune Diseases | 1 | 2018 | 2258 | 0.020 |
Why?
|
Intracellular Signaling Peptides and Proteins | 1 | 2016 | 2893 | 0.020 |
Why?
|
Cell Transformation, Neoplastic | 1 | 1995 | 2848 | 0.020 |
Why?
|
Leukocyte Count | 1 | 2009 | 1609 | 0.020 |
Why?
|
World Health Organization | 1 | 2011 | 1328 | 0.020 |
Why?
|
Proteomics | 1 | 2019 | 3914 | 0.020 |
Why?
|
Dimerization | 1 | 2006 | 886 | 0.010 |
Why?
|
Base Sequence | 1 | 2016 | 12430 | 0.010 |
Why?
|
Homeodomain Proteins | 1 | 2014 | 2431 | 0.010 |
Why?
|
Hematopoiesis | 1 | 1994 | 2059 | 0.010 |
Why?
|
Epoetin Alfa | 1 | 2004 | 78 | 0.010 |
Why?
|
Acute Disease | 1 | 1995 | 7245 | 0.010 |
Why?
|
Cell Cycle | 1 | 2012 | 2937 | 0.010 |
Why?
|
Papillomavirus Infections | 1 | 2016 | 1640 | 0.010 |
Why?
|
Tetrahydroisoquinolines | 1 | 2004 | 81 | 0.010 |
Why?
|
Clinical Trials, Phase II as Topic | 1 | 2006 | 640 | 0.010 |
Why?
|
Chi-Square Distribution | 1 | 2010 | 3438 | 0.010 |
Why?
|
Life Expectancy | 1 | 2010 | 1249 | 0.010 |
Why?
|
DNA Methylation | 1 | 2017 | 4432 | 0.010 |
Why?
|
Neoplasms, Germ Cell and Embryonal | 1 | 2008 | 496 | 0.010 |
Why?
|
CD4-Positive T-Lymphocytes | 1 | 1996 | 4413 | 0.010 |
Why?
|
Health Care Costs | 1 | 2016 | 3270 | 0.010 |
Why?
|
Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2011 | 1560 | 0.010 |
Why?
|
Inflammation | 1 | 2022 | 10868 | 0.010 |
Why?
|
Multidrug Resistance-Associated Proteins | 1 | 2002 | 105 | 0.010 |
Why?
|
Carcinoma, Renal Cell | 1 | 2017 | 3200 | 0.010 |
Why?
|
Body Mass Index | 1 | 2019 | 13055 | 0.010 |
Why?
|
Monocytes | 1 | 1990 | 2603 | 0.010 |
Why?
|
Kidney Neoplasms | 1 | 2017 | 4300 | 0.010 |
Why?
|
Plasmids | 1 | 2005 | 2269 | 0.010 |
Why?
|
Drug Carriers | 1 | 2004 | 710 | 0.010 |
Why?
|
Nuclear Proteins | 1 | 2014 | 5804 | 0.010 |
Why?
|
Ambulatory Care | 1 | 2010 | 2784 | 0.010 |
Why?
|
Drug Interactions | 1 | 2003 | 1418 | 0.010 |
Why?
|
Leukocytes | 1 | 2007 | 2034 | 0.010 |
Why?
|
Hemoglobins | 1 | 2004 | 1531 | 0.010 |
Why?
|
Skin | 1 | 2012 | 4506 | 0.010 |
Why?
|
Child | 2 | 2020 | 80960 | 0.010 |
Why?
|
Continuity of Patient Care | 1 | 2004 | 1076 | 0.010 |
Why?
|
Outpatients | 1 | 2005 | 1603 | 0.010 |
Why?
|
Physician-Patient Relations | 1 | 2010 | 3269 | 0.010 |
Why?
|
Gene Expression | 1 | 2010 | 7603 | 0.010 |
Why?
|
Hospitals | 1 | 2010 | 3904 | 0.010 |
Why?
|
Mental Health | 1 | 2010 | 3275 | 0.010 |
Why?
|
Transcription, Genetic | 1 | 2009 | 7609 | 0.010 |
Why?
|
Laparoscopy | 1 | 2006 | 2055 | 0.010 |
Why?
|
Transcription Factors | 1 | 2014 | 12174 | 0.010 |
Why?
|
Genome-Wide Association Study | 1 | 2013 | 12801 | 0.010 |
Why?
|
Proto-Oncogene Proteins c-raf | 1 | 1994 | 205 | 0.010 |
Why?
|
Blood Pressure | 1 | 2010 | 8544 | 0.010 |
Why?
|
Amino Acid Sequence | 1 | 2005 | 13427 | 0.010 |
Why?
|
Inpatients | 1 | 2005 | 2569 | 0.010 |
Why?
|
Multiple Myeloma | 1 | 2011 | 5196 | 0.010 |
Why?
|
Tomography, X-Ray Computed | 1 | 2016 | 20776 | 0.010 |
Why?
|
Molecular Sequence Data | 1 | 2005 | 17629 | 0.010 |
Why?
|
Lung Neoplasms | 1 | 2017 | 13594 | 0.010 |
Why?
|
Cross-Sectional Studies | 1 | 2013 | 26395 | 0.010 |
Why?
|
Precipitin Tests | 1 | 1992 | 816 | 0.010 |
Why?
|
Mammography | 1 | 2002 | 2434 | 0.010 |
Why?
|
GTPase-Activating Proteins | 1 | 1992 | 469 | 0.000 |
Why?
|
Cardiomyopathies | 1 | 2001 | 2057 | 0.000 |
Why?
|
Drug Therapy, Combination | 1 | 1999 | 6320 | 0.000 |
Why?
|
Models, Biological | 1 | 2004 | 9499 | 0.000 |
Why?
|
Cell Division | 1 | 1994 | 4478 | 0.000 |
Why?
|